Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Use of paper microfluidics in blood grouping === Recently, paper microfluidics was used in the fabrication of numerous immunological tests. Khan et al. in 2010 investigated a blood typing device based on the principle that red blood cell agglutination, triggered by specific antigeninteraction, drastically decreases blood wicking and transport on paper or chromatographic media. The concept was exhibited with a paper-based microfluidic device prototype, made from a filter paper shaped to a central zone with three extending channels. Each channel is treated with a different solution of antibody (Epiclone Anti-A, Anti-B, and Anti-D). Since μPADs were purposely created for use in resource-shortage conditions, it is highly important to provide the capability to analyze real samples like non-pretreated human blood and urine. This device is constructed to analyze whole-blood samples, which is an important step to increase the user acceptance of paper-based microfluidic diagnostics. The analysis is based on the wicking behavior of blood or antibody mixture on paper. Mixing blood samples with immunoglobulin M antibodies, specific for each blood group, causes agglutination of the red blood cells (RBC) by polymer bridging upon adsorption on the corresponding RBC antigens, and chromatographic separation of sample on the certain channel of the device occurs. Simultaneously, separation doesn't happen on hands soaked in non-specific antibody and the blood sample is weakened as a uniform and stable solution.
Stoolmiller AC, Horwitz AL, Dorfman A (1972). "Biosynthesis of the chondroitin sulfate proteoglycan. Purification and properties of xylosyltransferase". J. Biol. Chem. 247 (11): 3525–32. doi:10.1016/S0021-9258(19)45172-7. PMID 5030630. Gotting C, Kuhn J, Zahn R, Brinkmann T, Kleesiek K (2000). "Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II". J. Mol. Biol. 304 (4): 517–28. doi:10.1006/jmbi.2000.4261. PMID 11099377.
4-Methyl sterols are intermediates in the biosynthesis of 4-desmethyl sterols and are known to accumulate under anaerobic conditions. The synthesis of dinosterol begins with the cyclization of squalene to lanosterol, but then diverges from cholesterol biosynthesis. The biosynthesis of dinosterol's side chain has been investigated in dinoflagellates using methionine-[CD3]. The sequence of side-chain alkylations is thought to be initiated by the formation of 4α,24-dimethyl-5α-cholest-24(28)-en-3β-ol, followed by reduction to 4α,24-dimethyl-5α-cholestan-3β-ol, then introduction of the Δ22-double bond to form 4α,24-dimethyl-5α-cholest-22E-en-3β-ol and then methylation at C-23 to form 4α23,24-trimethyl- 5α-cholest-22E-en-3β-ol (dinosterol).
Wing Commander Christopher Andrew Wright, , Royal Air Force, 2653992B. Civil James Martin Ainscough. Lately Chief Executive Officer, Help Musicians. For services to Music and Musicians. Heather Margaret Patricia Akehurst. Chief Executive, Open Awards. For services to Further Education in Merseyside. Edward Jonathan Corcos Album. Founder, The Settle and Carlisle Railway Trust. For services to Railway Heritage and to the communities in the North of England. Genethlios Michael Anastassiades. Product and Lighting Designer. For services to Design. Andrew Robert James Anderson. Head, Maggie's Cancer Support Centre. For services to Cancer Support in the UK and Abroad. Dr. Claire Elizabeth Armstrong. Chief Executive Officer, Royal British Legion Scotland. For services to Veterans in Scotland. Nigel Christopher Ashton. Councillor, North Somerset Council. For Political and Public Service. Duncan Roy Barber. For services to the Defence Industry. Virginia Barrett. Principal and Chief Executive Officer, Farnborough College of Technology. For services to Further Education. Tiffany Crowell Beck. Chair of Trustees, Maritime Academy Trust. For services to Education. Elaine Bedell. Chief Executive Officer, Southbank Centre. For services to Business and to the Arts. Baldev Parkash Bhardwaj. For services to the community in Oldbury, West Midlands. Professor Maurice Biriotti. Chief Executive Officer, SHM Productions and Professor of Applied Humanities, University College London. For services to Business, to Academia and to Philanthropy. Antony Kenneth Blackburn. Broadcaster.
Sources: en.wikipedia.org
Genetic predisposition to substance use and a history of substance use increase the risk of persistent discontinuation syndrome symptoms. Treatment for physical withdrawal generally involves switching the patient to a long-acting benzodiazepine such as diazepam or clonazepam, then slowly titrating them off the replacement drug completely at a rate that is both reasonably comfortable for the patient but rapid enough for the managing physician to consider the rate of progress acceptable (overly rapid dose reduction greatly increases the risk of patient non-compliance, such as the use of illicitly obtained alternative sedatives and/or alcohol). Psychotherapy and cognitive behavioral therapy have demonstrated moderate success in reducing the rebound anxiety that results upon carisoprodol discontinuation but only when combined with regular and active attendance to a substance use support group. Carisoprodol withdrawal can be life-threatening (especially in high-dose users and those who attempt to quit "cold turkey"). Medical supervision is recommended, with gradual reduction of dose or a substitute medication, as with other depressant drugs.
=== Melted sample analysis === Methods used to study larger eukaryotes present in sea ice are also used to study other smaller microbes. Regardless of sea ice type, standard practice has been to eventually melt the collected sea ice sample before analysis for convenience. Analytical methods developed to investigate pelagic microbes can readily be applied to these melted sea ice samples. One drawback of this approach is that melting the sea ice exposes microbes accustomed to the hypersaline conditions of brine pockets and channels to significantly fresher water. The melting sea ice contains little-to-no salt, greatly diluting the salt concentration of the liquid phase of the sea ice sample. Osmotic shock and lysis may occur if the salinity decreases too much; additionally, careless warming of the sea ice sample may cause the microbes present to undergo thermal shock. One solution has been to melt the ice into a known volume of seawater kept at subzero temperatures filtered by pelagic microbes. This minimizes the decrease in salinity and drop in temperature and subsequently minimizes the loss of live microbes in the sample. Ice samples colder than –10 °C, however, will still see the loss of over half of the microbial population in the sample when using this approach.
== History == Shotgun proteomics arose from the difficulties of using previous technologies to separate complex mixtures. In 1975, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) was described by O’Farrell and Klose with the ability to resolve complex protein mixtures. The development of matrix-assisted laser desorption ionization (MALDI), electrospray ionization (ESI), and database searching continued to grow the field of proteomics. However these methods still had difficulty identifying and separating low-abundance proteins, aberrant proteins, and membrane proteins. Shotgun proteomics emerged as a method that could resolve even these proteins.
=== Canada === Health Canada classifies VOCs as organic compounds that have boiling points roughly in the range of 50 to 250 °C (122 to 482 °F). The emphasis is placed on commonly encountered VOCs that would have an effect on air quality.
Aromatic L-amino acid decarboxylase (AADC or AAAD), also known as DOPA decarboxylase (DDC), tryptophan decarboxylase, and 5-hydroxytryptophan decarboxylase, is a lyase enzyme (EC 4.1.1.28), located in region 7p12.2-p12.1.
Sources: en.wikipedia.org
The Gulf War was an armed conflict between Iraq and a 42-country coalition led by the United States in response to Saddam Hussein invading neighboring Kuwait on 2 August 1990. The coalition's efforts were in two phases: Operation Desert Shield, which marked the military buildup from August 1990 to January 1991; and Operation Desert Storm, from the bombing campaign against Iraq on 17 January until the American-led liberation of Kuwait on 28 February. The invasion of Kuwait was met with immediate international condemnation. The UN Security Council demanded Iraq's immediate withdrawal and imposed a total embargo on products from Iraq and Kuwait. A coalition began a military buildup in the Persian Gulf region. The broadest military alliance since World War II, its largest contributors were the US, Saudi Arabia, the United Kingdom, and Egypt. The Security Council issued an ultimatum to Iraq on 29 November 1990, expiring on 15 January 1991, to withdraw from Kuwait, with member-states thereafter empowered to use "all necessary means" to force withdrawal. On 17 January, the coalition began aerial and naval bombardment of Iraq and Kuwait, which continued for five weeks. Iraq fired missiles at Israel and at Saudi Arabia, but failed to split Muslim-majority countries from the coalition. On 24 February 1991, the coalition launched a decisive ground assault liberating Kuwait and promptly advancing into Iraqi territory. The coalition halted its ground advance after one hundred hours, and declared a ceasefire.
== Activity == Despite its alternative name (enterokinase), enteropeptidase is a serine protease that catalyses the hydrolysis of peptide bonds in proteins and, unlike other kinases, does not catalyze transfer of phosphate groups. Enteropeptidase exhibits trypsin-like activity, cleaving proteins following a lysine at a specific cleavage site (Asp-Asp-Asp-Asp-Lys). This cleavage results in trypsindependent activation of other pancreatic zymogens, such as chymotrypsinogen, proelastase, procarboxypeptidase and prolipase in the lumen of the gut. As the pro-region of trypsinogen contains this sequence, enteropeptidase catalyses its activation in vivo: trypsinogen → trypsin + pro-region (Val-Asp-Asp-Asp-Asp-Lys)
American Solidarity Party: Peter Sonski, Connecticut school board member Approval Voting Party: Blake Huber, activist and nominee for president in 2020 Constitution Party: Randall Terry, anti-abortion activist and perennial candidate Independent American Party: Joel Skousen, survivalist and consultant Natural Law Party: Robert F. Kennedy Jr., environmental lawyer and author, the party's nominee in addition to his run as an independent before he withdrew from the race ahead of the election but was not removed from ballots Party for Socialism and Liberation: Claudia De la Cruz, political activist Prohibition Party: Michael Wood, businessman Socialist Equality Party: Joseph Kishore, writer and SEP nominee in 2020 Socialist Party USA: Bill Stodden, nonprofit executive Socialist Workers Party: Rachele Fruit, hotel worker and trade unionist
==== Film and Television School ==== From January 1991, the ownership and management of the Swinburne Film and Television School (founded 1966) was handed over to VCA, becoming the VCA Film and Television School. Per an announcement in Filmnews in August 1990, the Swinburne Film and Television School was officially transferred to the VCA from January 1991, but would stay at Swinburne until it was able to move to a new building in South Melbourne (funded by $12m from the federal government) in 1993. VCA would merge with Melbourne University during 1991. The VCA's School of Film and Television remained at Hawthorn until 1 July 1994, when it moved into a purpose-built federally funded building on the VCA campus at Southbank. In April 2002, the congress of the CILECT (Centre International de Liaison des Ecoles de Cinema et de Television), the international association of the world's major film and television schools, was held at VCA. As of 2024 the VCA Film and Television Archive holds around 1,700 short films dating from 1967, which includes the work produced by graduating students of Swinburne Film and Television School students as well as students and faculty of the VCA School of Film and Television School and the Melbourne Conservatorium of Music.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.